114899-80-8

Basic information

• Product Name: Spiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1'(2'H)-isoquinoline]-14-carbonitrile,5-(acetyloxy)-3',4',6,6a,7,13,14,16-octahydro-6',8-dihydroxy-7',9-dimethoxy-4,10,23-trimethyl-19-oxo-,(1'R,6R,6aR,7R,13S,14R,16R)-
• Synonyms: Spiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1'(2'H)-isoquinoline]-14-carbonitrile,5-(acetyloxy)-3',4',6,6a,7,13,14,16-octahydro-6',8-dihydroxy-7',9-dimethoxy-4,10,23-trimethyl-19-oxo-,[6R-(6a,6ab,7b,13b,14b,16a,20R*)]-; Ecteinascidin 770; Ecteinascidine 770; Et 770
• CAS NO: 114899-80-8
• Molecular Formula: C40H42 N4 O10 S
• Molecular Weight: 770.86
• Mol File: 114899-80-8.mol
• Article Data: 16

Chemical Properties

• CAS DataBase Reference: Spiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1'(2'H)-isoquinoline]-14-carbonitrile,5-(acetyloxy)-3',4',6,6a,7,13,14,16-octahydro-6',8-dihydroxy-7',9-dimethoxy-4,10,23-trimethyl-19-oxo-,(1'R,6R,6aR,7R,13S,14R,16R)-(CAS DataBase Reference)
• NIST Chemistry Reference: Spiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1'(2'H)-isoquinoline]-14-carbonitrile,5-(acetyloxy)-3',4',6,6a,7,13,14,16-octahydro-6',8-dihydroxy-7',9-dimethoxy-4,10,23-trimethyl-19-oxo-,(1'R,6R,6aR,7R,13S,14R,16R)-(114899-80-8)
• EPA Substance Registry System: Spiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1'(2'H)-isoquinoline]-14-carbonitrile,5-(acetyloxy)-3',4',6,6a,7,13,14,16-octahydro-6',8-dihydroxy-7',9-dimethoxy-4,10,23-trimethyl-19-oxo-,(1'R,6R,6aR,7R,13S,14R,16R)-(114899-80-8)

Safety Data

• Hazardous Substances Data: 114899-80-8(Hazardous Substances Data)

Upstream product

• 290813-45-5 C₄₈H₄₉Cl₃N₄O₁₀S 
• 182201-65-6 C₄₀H₅₇N₃O₁₀Si₂ 
• 182201-71-4 C₃₃H₃₈N₄O₉S 
• 182201-63-4 C₃₃H₃₅N₃O₁₀S 
• 182201-58-7 C₃₁H₃₃N₃O₉ 
• 203922-33-2 C₃₁H₃₅N₃O₁₀ 
• 182201-60-1 C₂₈H₃₃N₃O₈ 
• 182201-50-9 (S)-2-Benzyloxycarbonylamino-3-(6-benzyloxy-7-methyl-benzo[1,3]dioxol-5-yl)-propionic acid 2,2-dimethoxy-ethyl ester 
• 203922-27-4 (S)-2-Benzyloxycarbonylamino-3-(6-benzyloxy-7-methyl-benzo[1,3]dioxol-5-yl)-propionic acid 2-oxo-ethyl ester 
• 182201-51-0 C₂₈H₂₅NO₇ 
• 203921-96-4 2-[1-(6-Benzyloxy-7-methyl-benzo[1,3]dioxol-5-yl)-meth-(E)-ylidene]-malonic acid allyl ester 2,2-dimethoxy-ethyl ester 
• 182201-54-3 (S)-2-Allyloxycarbonylamino-3-[3,5-bis-(tert-butyl-dimethyl-silanyloxy)-4-methoxy-phenyl]-propionic acid methyl ester 
• 182201-56-5 {(S)-2-[3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-4-methoxy-phenyl]-1-formyl-ethyl}-carbamic acid allyl ester 
• 203922-28-5 2-[1-[3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-4-methoxy-phenyl]-meth-(E)-ylidene]-malonic acid monomethyl ester 

Downstream Products

• 1326247-50-0 18,6'-O-bisallyl-2'-N-benzoyl-ecteinascidin 770 
• 1326247-53-3 18,6'-O-bisallyl-2'-N-(4''-nitrobenzoyl)-ecteinascidin 770 
• 1326247-56-6 18,6'-O-bisallyl-2'-N-(3''-nitrobenzoyl)-ecteinascidin 770 
• 1326247-66-8 18,6'-O-bisallyl-2'-N-(4''-bromobenzoyl)-ecteinascidin 770 
• 1326247-67-9 18,6'-O-bisallyl-2'-N-(2''-bromobenzoyl)-ecteinascidin 770 
• 1326247-68-0 2'-N-Bz-Et 770 
• 1326247-70-4 2'-N-(4-nitroBz)-Et 770 
• 1326247-72-6 2'-N-(3-nitroBz)-Et 770 
• 1326247-83-9 18,6'-O-bisallyl-2'-N-cinnamoyl-ecteinascidin 770 
• 1326247-85-1 18,6'-O-bisallyl-2'-N-(4''-nitrocinnamoyl)-ecteinascidin 770 
• 1326247-86-2 2'-N-cinnamoyl-ecteinascidin 770 
• 1326247-89-5 C₅₂H₅₂N₄O₁₁S 
• 114899-77-3 ecteinascidin 743 

Relevant articles and documents

Ecteinascidins 729, 743, 745, 759A, 759B, and 770: Potent Antitumor Agents from the caribbean Tunicate Scteinascidia turbinata

Ecteinascidins 729, 743, 745, 759A, 759B and 770, tris(tetrahydroisoquinolines) with potent in vivo antitumor activity, have been isolated from the colonial tunicate Ecteinascidia turbinate, and their structures have been assigned.

IMPROVED PROCESS FOR THE PREPARATON OF PURE (1'R,6R,6aR,7R,13S,14S,16R)-5-(ACETYLOXY)-3',4',6,6a,7,13,14,16-OCTAHYDRO-6',8,14-TRIHYDROXY-7',9-DIMETHOXY-4,10,23-TRIMETHYLSPIRO[6,16-(EPITHIOPROPANOXYMETH ANO)-7,13-IMINO-12H-1,3-DIOXOLO[7,8]ISOQUINO[3,2-b][3]BENZAZOCINE-20,1'(2'H)-ISOQUINOLIN]-19-ONE POLYMORPH THERE OF

The present invention provides pure (1'R,6R,6aR,7R,13S,14S,16R)-5-(acetyloxy)-3',4',6,6a,7,13,14,16-octahydro-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl spiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino [3,2-b][3] benzazocine-20,1'(2'H)-isoquinolin]-19-one of formula (1) substantially free from one or more impurities selected from intermediate compound of formula (50), cyclic impurity of formula (A), deshydroxy impurity of formula (B) and hydroxy impurity of formula (C).

A Scalable Total Synthesis of the Antitumor Agents Et-743 and Lurbinectedin

An efficient and scalable approach is described for the total synthesis of the marine natural product Et-743 and its derivative lubinectedin, which are valuable antitumor compounds. The method delivers 1.6 % overall yield in 26 total steps from Cbz-protected (S)-tyrosine. It features the use of a common advanced intermediate to create the right and left parts of these compounds, and a light-mediated remote C?H bond activation to assemble a benzo[1,3]dioxole-containing intermediate.